FDA 483 - Sunrise Pharmaceutical, Inc. - January 18, 2018

An FDA inspection of Sunrise Pharmaceutical, Inc. in Rahway, NJ, revealed a significant deficiency in their quality system. The firm failed to conduct ongoing GMP training for approximately (b)(4) employees involved in production, packaging, and quality control operations. This indicates a lack of assurance that employees are familiar with current Good Manufacturing Practice requirements.